Australian news, and some related international items

Cyclotron-produced technetium-99m approved by Health Canada

these cyclotrons can be used to reliably create technetium-99m regionally and without the need for reactor-based materials.

Cyclotron-produced technetium-99m approved by Health Canada, TRIUMF, 

17 December 2020  Over the last 50 years, technetium-99m has driven unparalleled advances in the development of non-invasive imaging techniques and, in turn, our understanding of disease.

Now, a new cyclotron-based approach to producing this critical diagnostic tool has received Health Canada approval, greenlighting the made-in-Canada technology for national implementation and opening the door to a greener, more reliable way to make technetium-99m. 

The approval represents a critical milestone for the TRIUMF-led Cyclomed99 consortium, which spearheaded the innovative research effort. The consortium, including partners BC Cancer, the University of British Columbia (UBC), the Lawson Health Research Institute, and the Centre for Probe Development and Commercialization, is the first in the world to obtain full regulatory approval for cyclotron-based production.

It also a turning point for the consortiums licensee ARTMS Inc., the TRIUMF spin-off company bringing this technology to market. ARTMS’ technology makes technetium-99m production possible on many of the world’s most common medical cyclotrons, enabling regional production of this critical isotope within local communities. 

“Medical isotopes help so many people every day. It’s critical to have a stable, multi-faceted supply chain to avoid unexpected disruptions to their availability,” said Paul Schaffer, Associate Laboratory Director, Life Sciences at TRIUMF and Associate Professor at UBC’s Faculty of Medicine. “The approval of cyclotron-produced technetium-99m by Health Canada is an important milestone for this Canadian innovation that will ultimately deliver direct benefit for Canadian patients.”

While the Health Canada approval brings new promise for patients and researchers, it also highlights an important chapter in Canadian innovation, one which saw a focused national research effort produce an effective solution to a global problem.

The path towards cyclotron-produced technetium-99m ……

In 2009, following unplanned disruptions at NRU (which historically provided up to half of the world’s technetium-99m via molybdenum-99 generators), the Government of Canada initiated the Non-reactor-based Isotope Supply Contribution Program (NISP) which challenged researchers to find a new way to produce critical medical isotopes—in particular, technetium-99m.

Led by Schaffer and TRIUMFs Dr. Tom Ruth, scientists and engineers from TRIUMF joined partners at BC Cancer, the Centre for Probe Development Commercialization (CPDC), the Lawson Health Research Institute, and the University of British Columbia to launch a national collaboration to answer the NISP call:  the CycloMed99 consortium.

A new way to produce technetium-99m

The consortium’s proposal detailed a new and innovative technology to enable the production of technetium-99m using medical cyclotrons. These compact particle accelerators already operate in regional healthcare centres worldwide, producing isotopes by bombarding a target material with a proton beam and extracting the desired species. The process is safe and precise, employing stable targets and producing little to no long-lived radioactive waste. And, with the right target and extraction systems, these cyclotrons can be used to reliably create technetium-99m regionally and without the need for reactor-based materials.

“Cyclotron centres across Canada can produce these isotopes locally and on-demand, and we have shown the path that can be used to achieve regulatory approval,” said Francois Bénard, senior executive director of research at BC Cancer, professor of radiology and associate dean of research at UBC’s faculty of medicine. “The same approach can be followed at other sites in Canada and internationally. This has been a shared vision of many researchers across the country, and we have to recognize the many collaborators who worked for years to make this announcement possible.”  

This bright future will first take shape at TRIUMFInstitute for Advanced Medical Isotopes (IAMI), where a state-of-the-art TR-24 medical cyclotron will offer production capacity for the Lower Mainlands technetium-99 needsIn additionIAMI will serve as a hub for radiopharmaceutical research, providing access to leading-edge facilities and expertise in accelerator technology and isotope science. The Institute will further catalyze the Vancouver region’s diverse nuclear medicine sector by convening researchers, students, academic collaborators, not-for-profits, government, and industry partners.

With support from the Canadian government and our partners, we have developed an effective solution to the medical isotope crisis, one that will improve health outcomes and reaffirm Canada’s role as a global leader in isotope production and research. … …

January 7, 2021 - Posted by | General News

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: